UNIV HEALTH NETWORK UHN has a total of 20 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2010. It filed its patents most often in EPO (European Patent Office), WIPO (World Intellectual Property Organization) and Canada. Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are MEDICINAL BIOCONVERGENCE RES CT, CEMM FORSCHUNGSZENTRUM FUER MOLEKULARE MEDIZIN GMBH and Université de Montréal .
# | Country | Total Patents | |
---|---|---|---|
#1 | EPO (European Patent Office) | 14 | |
#2 | WIPO (World Intellectual Property Organization) | 5 | |
#3 | Canada | 1 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement | |
#4 | Organic fine chemistry | |
#5 | Medical technology |
# | Technology | |
---|---|---|
#1 | Therapeutic chemical compounds | |
#2 | Medical preparations | |
#3 | Analysing materials | |
#4 | Peptides | |
#5 | Microorganisms | |
#6 | Measuring microorganism processes | |
#7 | Special acyclic compounds | |
#8 | Diagnosis and surgery | |
#9 | Heterocyclic compounds | |
#10 | Fermentation |
# | Name | Total Patents |
---|---|---|
#1 | Murata Kenji | 3 |
#2 | Hirano Naoto | 3 |
#3 | Rahman Muhammed Aashiq | 3 |
#4 | Nakatsugawa Munehide | 3 |
#5 | Zheng Gang | 3 |
#6 | Erdman Laura | 2 |
#7 | Conroy Andrea | 2 |
#8 | Liles Conrad W | 2 |
#9 | Korytnikov Roman | 2 |
#10 | Mcgaugh Emily | 2 |
Publication | Filing date | Title |
---|---|---|
WO2019227198A1 | Methods and compositions comprising tankyrase inhibitors for generating insulin producing cells | |
EP3362785A1 | Electrochemical assay for a protein analyte | |
EP2766352A1 | Indazole compounds as kinase inhibitors and method of treating cancer with same | |
WO2011041914A1 | Use of flubendazole and vinca alkaloids for treatment of hematological diseases | |
EP2488206A1 | Porphyrin nanovesicles | |
EP2419111A1 | Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof | |
WO2010102387A1 | Interleukin-12 polymorphisms for identifying risk for primary biliary cirrhosis |